There is disclosed compositions and methods relating to or derived from anti-PSMA antibodies. More specifically, there is disclosed fully human antibodies that bind PSMA, PSMA-antibody binding fragments and derivatives of such antibodies, and PSMA-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease. There is further disclosed targeted therapies for treatment of prostate cancer having the disclosed anti-PSMA antibodies and fragments thereof targeting the therapeutic agent or cell.本發明揭示與抗-PSMA抗體有關或源自於抗-PSMA抗體之組合物及方法。更特定言之，本發明揭示結合PSMA之完全人類抗體、PSMA-抗體結合片段及此類抗體之衍生物，及包含此類片段之PSMA結合多肽。另外，本發明揭示編碼此類抗體、抗體片段以及衍生物及多肽之核酸，包含此類聚核苷酸之細胞，製備此類抗體、抗體片段以及衍生物及多肽之方法，以及使用此類抗體、抗體片段以及衍生物及多肽之方法，包括治療疾病之方法。本發明進一步揭示用於治療前列腺癌之靶向療法，其具有靶向治療劑或細胞的所揭示之抗-PSMA抗體及其片段。
